Ross Bacon, MD
Pulmonary Disease · Sioux Falls, SDNPI 1366528838
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Intuitive Surgical at 27.3% of the total. That places this record below the midpoint for pulmonary disease clinicians in SD, where the typical reported total is $424.
Across 29 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$164
- Mylan Specialty L.p.$79
- Grifols USA, LLC$72
- AstraZeneca$54
- Sunovion Pharmaceuticals Inc.$47
- Regeneron Healthcare Solutions, Inc.$43
- plus $140 from 8 others
What the payments were for
- Food & beverage$57295%
- Education$285%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $164 |
| Mylan Specialty L.p. | 5 | $79 |
| Grifols USA, LLC | 5 | $72 |
| AstraZeneca | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| GSK | 3 | $43 |
| Insmed, Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
| Merck | 1 | $11 |
| United Therapeutics Corporation | 1 | $11 |
How this compares
$599 in reported general payments places this provider in the 50th percentile of 35 pulmonary disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 222 | $188,431 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 141 | $93,327 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $32,126 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $22,570 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $16,481 |
| DuleraMometasone/Formoterol | 32 | $10,792 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $9,870 |
| Spiriva RespimatTiotropium Bromide | 14 | $9,418 |
| Arnuity ElliptaFluticasone Furoate | 23 | $7,682 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $5,566 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $4,441 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,828 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $3,801 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $3,778 |
| Azithromycin | 129 | $2,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $43 | $248,549355 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $54 | $98,892166 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $13 | $31,98752 claims |
| MerckDulera | $11 | $10,79232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 35 pulmonary disease providers in South Dakota.
Other pulmonary disease in Sioux Falls
- Joevasanth DevasahayamSioux Falls$8K
- Matthew TaylorSioux Falls$8K
- Fady JamousSioux Falls$6K
- Rizan HajalSioux Falls$5K
- Kaitlin BranickSioux Falls$5K
- Anna PlemmonsSioux Falls$3K
- Mohammed AwadSioux Falls$2K
- Ashraf ElshamiSioux Falls$2K
- John YuSioux Falls$2K
- Rajaganesh RajagopalanSioux Falls$964
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.